Aemetis (NASDAQ: AMTX) is one of 25 public companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its rivals? We will compare Aemetis to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.
Insider and Institutional Ownership
15.9% of Aemetis shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Industrial organic chemicals” companies are owned by institutional investors. 24.1% of Aemetis shares are owned by insiders. Comparatively, 14.0% of shares of all “Industrial organic chemicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Aemetis and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aemetis||$150.15 million||-$30.30 million||-1.53|
|Aemetis Competitors||$3.36 billion||$346.13 million||4.16|
Aemetis’ rivals have higher revenue and earnings than Aemetis. Aemetis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Aemetis has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500. Comparatively, Aemetis’ rivals have a beta of 0.49, meaning that their average stock price is 51% less volatile than the S&P 500.
This table compares Aemetis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Aemetis and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aemetis currently has a consensus price target of $2.00, suggesting a potential upside of 47.06%. As a group, “Industrial organic chemicals” companies have a potential upside of 15.32%. Given Aemetis’ higher probable upside, equities research analysts clearly believe Aemetis is more favorable than its rivals.
Aemetis rivals beat Aemetis on 10 of the 13 factors compared.
Aemetis, Inc. operates as an international renewable fuels and bio-chemicals company in North America and India. It focuses on the production of advanced fuels and chemicals through the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into advanced bio refineries. The company owns and operates a biodiesel plant in Kakinada, India; and an ethanol plant in Keyes, California. Aemetis, Inc. sells biodiesel and glycerin to resellers, distributors, and refiners through its sales force and independent sales agents, as well as to brokers who resell the product to end-users. It also produces ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.